Clinical and Echocardiographic Parameters as Risk Factors for Atrial Fibrillation (AF) in Patients with Hyperthrophic Cardiomyopathy (HCM)

Atrial Fibrillation

Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation

Circulation.

Weng LC, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B, Trinquart L, McManus DD, Staerk L, Lin H, Lunetta KL, Ellinor PT, Benjamin EJ, Lubitz SA

doi: 10.1161/CIRCULATIONAHA.

Atrial FibrillationHeart, Artery and Coronary DiseasesHeart FailureThrombosis and StrokeTherapy and Intervention

Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy

Circulation.

Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM 3rd, Maron MS, Maron BJ

doi: 10.1161/

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation

JAMA Cardiol.

Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, Olesen JB, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL

doi: 10.1001/jamacardio.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Circ Arrhythm Electrophysiol.

Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E

doi: 10.1161/CIRCEP.116.004267.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study

JAMA Cardiol.

Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD; REVEAL AF Investigators

doi: 10.1001/

Atrial FibrillationTherapy and Intervention

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

Circ Cardiovasc Interv.

Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP

doi: 10.1161/CIRCINTERVENTIONS.119.008349.

Atrial Fibrillation

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies

J Am Heart Assoc.

Brouwer TF, Whang W, Kuroki K, Halperin JL, Reddy VY

doi: 10.1161/JAHA.119.013525.

Atrial Fibrillation

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Circulation.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA

doi: 10.1161/CIRCULATIONAHA.

Atrial FibrillationHeart FailureThrombosis and StrokeFurther Publications

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry

JAMA Cardiol.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK, GARFIELD-AF Investigators.

doi: 10.1001/jamacardio.2018.4729.

Related content

Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation

Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

Net Clinical Benefit of Left Atrial Appendage Closure Versus Warfarin in Patients With Atrial Fibrillation: A Pooled Analysis of the Randomized PROTECT-AF and PREVAIL Studies

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry